ARTICLE | Clinical News
Abgenix begins Phase II
July 31, 2001 7:00 AM UTC
ABGX and partner Immunex (IMNX) began a North American Phase II study of ABX-EGF human monoclonal antibody against the EGF receptor to treat non-small cell lung cancer. The 210-patient trial will asse...